Tags

Type your tag names separated by a space and hit enter

Regression of left ventricular hypertrophy in kidney transplant recipients: the potential role for inhibition of mammalian target of rapamycin.
Transplant Proc. 2010 Nov; 42(9 Suppl):S41-3.TP

Abstract

Left ventricular hypertrophy (LVH) contributes to elevated cardiac mortality with graft function in renal transplant recipients. Antihypertensive therapy, and especially angiotensin-converting enzyme (ACE) inhibitors, proved to be effective in regressing the LVH of renal transplant recipients, at least in part by interacting with immunosuppressive agents, thus raising the possibility that immunosuppressive therapy might affect changes in the left ventricular mass (LVM) of recipients. This review mainly focuses on the potential role of mammalian target of rapamycin (mTOR) inhibition to regress cardiac hypertrophy in both experimental models and in the clinical setting. We comment on the results of experimental studies conducted on animal models, which showed regression of cardiac hypertrophy by sirolimus (SRL). We also discuss clinical studies that show that conversion from calcineurin inhibitors to SRL is effective to achieve regression of LVH in both kidney and cardiac transplant recipients, mainly by reducing the true left ventricular wall hypertrophy.

Authors+Show Affiliations

Divisione di Nefrologia, Dialisi e Trapianto, Azienda Ospedaliera Universitaria San Martino, Genova, Italy. ernesto.paoletti@hsanmartino.itNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

21095451

Citation

Paoletti, E, and G Cannella. "Regression of Left Ventricular Hypertrophy in Kidney Transplant Recipients: the Potential Role for Inhibition of Mammalian Target of Rapamycin." Transplantation Proceedings, vol. 42, no. 9 Suppl, 2010, pp. S41-3.
Paoletti E, Cannella G. Regression of left ventricular hypertrophy in kidney transplant recipients: the potential role for inhibition of mammalian target of rapamycin. Transplant Proc. 2010;42(9 Suppl):S41-3.
Paoletti, E., & Cannella, G. (2010). Regression of left ventricular hypertrophy in kidney transplant recipients: the potential role for inhibition of mammalian target of rapamycin. Transplantation Proceedings, 42(9 Suppl), S41-3. https://doi.org/10.1016/j.transproceed.2010.07.007
Paoletti E, Cannella G. Regression of Left Ventricular Hypertrophy in Kidney Transplant Recipients: the Potential Role for Inhibition of Mammalian Target of Rapamycin. Transplant Proc. 2010;42(9 Suppl):S41-3. PubMed PMID: 21095451.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Regression of left ventricular hypertrophy in kidney transplant recipients: the potential role for inhibition of mammalian target of rapamycin. AU - Paoletti,E, AU - Cannella,G, PY - 2010/11/25/entrez PY - 2010/12/9/pubmed PY - 2011/3/16/medline SP - S41 EP - 3 JF - Transplantation proceedings JO - Transplant Proc VL - 42 IS - 9 Suppl N2 - Left ventricular hypertrophy (LVH) contributes to elevated cardiac mortality with graft function in renal transplant recipients. Antihypertensive therapy, and especially angiotensin-converting enzyme (ACE) inhibitors, proved to be effective in regressing the LVH of renal transplant recipients, at least in part by interacting with immunosuppressive agents, thus raising the possibility that immunosuppressive therapy might affect changes in the left ventricular mass (LVM) of recipients. This review mainly focuses on the potential role of mammalian target of rapamycin (mTOR) inhibition to regress cardiac hypertrophy in both experimental models and in the clinical setting. We comment on the results of experimental studies conducted on animal models, which showed regression of cardiac hypertrophy by sirolimus (SRL). We also discuss clinical studies that show that conversion from calcineurin inhibitors to SRL is effective to achieve regression of LVH in both kidney and cardiac transplant recipients, mainly by reducing the true left ventricular wall hypertrophy. SN - 1873-2623 UR - https://www.unboundmedicine.com/medline/citation/21095451/Regression_of_left_ventricular_hypertrophy_in_kidney_transplant_recipients:_the_potential_role_for_inhibition_of_mammalian_target_of_rapamycin_ DB - PRIME DP - Unbound Medicine ER -